State Coverage and Reimbursement of Antiobesity Medications in Medicaid
JAMA · 09.04.2024 · 331 (14) · 1230
DOI: 10.1001/jama.2024.3073 ↗Kurz gefasst
Fachartikel in der Zeitschrift JAMA, erschienen am 09.04.2024. Verfasst von Benjamin Y Liu und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, Beth Israel Deaconess Medical Center, Boston, Massachusetts. Hauptthemen laut MEDLINE: Anti-Obesity Agents, Glucagon-Like Peptide-1 Receptor Agonists, Insurance Coverage, Insurance, Health, Reimbursement. Die Arbeit wurde bisher 51-mal zitiert (Crossref) und nennt 5 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
This study examines state Medicaid coverage policies for antiobesity medications and their trends in Medicaid reimbursement from 2011 to 2022.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Medicine, Beth Israel Deaconess Medical Center, Boston, Massachusetts.
- Division of Pharmacoepidemiology and Pharmacoeconomics, Brigham and Women's Hospital, Boston, Massachusetts.
Zitieren
APA
Liu, B. Y., & Rome, B. N. (2024). State Coverage and Reimbursement of Antiobesity Medications in Medicaid. JAMA, 331(14), 1230. https://doi.org/10.1001/jama.2024.3073
Vancouver
Liu BY, Rome BN. State Coverage and Reimbursement of Antiobesity Medications in Medicaid. JAMA. 2024;331(14):1230. doi:10.1001/jama.2024.3073
BibTeX
@article{Liu2024,
author = {Liu, Benjamin Y and Rome, Benjamin N},
title = {State Coverage and Reimbursement of Antiobesity Medications in Medicaid},
journal = {JAMA},
year = {2024},
volume = {331},
number = {14},
pages = {1230},
doi = {10.1001/jama.2024.3073}
}
EUVIMED